Bristol Myers sales fall, cuts 2023 forecast as drugs face competition
Jul 27th, 2023
Copyright© 2023 SWORD CAPITAL | All Rights Reserved
Sword Capital is a registered and reserved Trademark for Sword Capital Companies worldwide, working in the field of International Financial Brokerage. It also serves its clients from individuals and financial institutions in Asia, Africa, Europe, Australia, South America.
Sword Capital (Kuwait) is regulated by CMA License No AP/20019/0002 (Prime Brokerage)
This is the official Sword Capital Global (www.sword-capital.com) website and authorizes Sword Capital Companies to use it in accordance with the Authority and Licenses of each Company which has been Authorized by Financial Control Authority. As for Sword Capital representative offices, they do not engage the activity but only receive client complaints.
Sword Capital Trademark is reserved worldwide and is only used by Sword Capital companies, which are accredited by Sword Capital Kuwait and any illegal use is held accountable in any country in the world.
Sword Capital does not offer its services to residents of certain jurisdictions such as USA, Iran, Cuba, Sudan, Syria, North Korea or any country restricted by FATF
Risk Warning: Global Securities Trading involves significant risk to your invested capital. Please read and ensure you fully understand our Risk Disclosure.